SCHEMBL13499150

SCHEMBL13499150

CC(C)(C)OC(=O)N[C@@H]1CCCc2cc(CC3SCCCS3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
BDKRB1 P46663 8/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4524080 0.90 ALDH1A1 (0.38) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL4524083 0.90 ALDH1A1 (0.38) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL5407348 0.84 BDKRB1 (0.43) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL1725049 0.84 ALDH1A1 (0.44) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL13936477 0.84 ALDH1A1 (0.44) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL1725050 0.84 ALDH1A1 (0.44) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL3537141 0.83 CFD (0.49) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL3532767 0.83 ALDH1A1 (0.43) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL3537138 0.83 CFD (0.49) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1
SCHEMBL3532766 0.83 ALDH1A1 (0.43) ALDH1A1TAS1R3TAS1R1TAS1R2BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662811-B2 N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases AMGEN INC. (US) 2010-02-16 US disclosed